Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia

Schizophrenia Research

Volumn 83, Issue 2-3, 2006, Pages 201-210

  Xiang, Ying Qiang ^a   Zhang, Zhang Jin ^b   Weng, Yong Zhen ^a   Zhai, Yi Min ^a   Li, Wen Biao ^a   Cai, Zhuo Ji ^a   Tan, Qing Rong ^b   Wang, Chuan Yue ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Clozapine; Norclozapine; Relapse; Schizophrenia; Serum concentration

Indexed keywords

CLOZAPINE; DRUG METABOLITE; NORCLOZAPINE;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MALE; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; RELAPSE; RISK; SCHIZOPHRENIA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; SCHIZOPHRENIA; STATISTICS; TIME FACTORS;

EID: 33646469840     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.01.011     Document Type: Article

References (35)

1. Chong M.Y., Tan C.H., Fujii S., Yang S.Y., Ungvari G.S., Si T., Chung E.K., Sim K., Tsang H.Y., and Shinfuku N. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin. Neurosci. 58 (2004) 61-67
2. Dettling M., Sachse C., Brockmoller J., Schley J., Muller-Oerlinghausen B., Pickersgill I., Rolfs A., Schaub R.T., and Schmider J. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology (Berlin) 152 (2000) 80-86
3. Diaz F.J., de Leon J., Josiassen R.C., Cooper T.B., and Simpson G.M. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr. Res. 72 (2005) 131-135
4. Gaertner I., Gaertner H.J., Vonthein R., and Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J. Clin. Psychopharmacol. 21 (2001) 305-310
5. Gaszner P., and Makkos Z. Clozapine maintenance therapy in schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 28 (2004) 465-469
6. Gaszner P., Makkos Z., and Kosza P. Agranulocytosis during clozapine therapy. Prog. Neuro-psychopharmacol. Biol. Psychiatry 26 (2002) 603-607
7. Guitton C., Abbar M., Kinowski J.M., Chabrand P., and Bressolle F. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 18 (1998) 470-476
8. Hamann J., Leucht S., and Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 36 (2003) 18-26
9. Haring C., Fleischhacker W.W., Schett P., Humpel C., Barnas C., and Saria A. Influence of patient-related variables on clozapine plasma levels. Am. J. Psychiatry 147 (1990) 1471-1475
10. Hasegawa M., Gutierrez-Esteinou R., Way L., and Meltzer H.Y. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J. Clin. Psychopharmacol. 13 (1993) 383-390
11. Heiser P., Schulte E., Hausmann C., Becker R., Remschmidt H., Krieg J.C., and Vedder H. Effects of clozapine and its metabolites on the 5-HT2 receptor system in cortical and hippocampal cells in vitro. Prog. Neuro-psychopharmacol. Biol. Psychiatry 28 (2004) 297-302
12. Honigfeld G., Arellano F., Sethi J., Bianchini A., and Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J. Clin. Psychiatry 59 S (1998) 3-7
13. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45 (1988) 789-796
14. Lane H.Y., Chang Y.C., Chang W.H., Lin S.K., Tseng Y.T., and Jann M.W. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J. Clin. Psychiatry 60 (1999) 36-40
15. Lee M.A., Jayathilake K., and Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37 (1999) 1-11
16. Llorca P.M., Lancon C., Disdier B., Farisse J., Sapin C., and Auquier P. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. J. Psychiatry Neurosci. 27 (2002) 30-37
17. Masellis M., Basile V.S., Ozdemir V., Meltzer H.Y., Macciardi F.M., and Kennedy J.L. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol. Psychiatry 47 (2000) 252-266
18. Mauri M.C., Volonteri L.S., Dell'Osso B., Regispani F., Papa P., Baldi M., and Bareggi S.R. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J. Clin. Psychopharmacol. 23 (2003) 660-664
19. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., and Potkin S. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60 (2003) 82-91
20. Odou P., Frimat B., Fontaine B., Luyckx M., Brunet C., Robert H., Dine T., Gressier B., Cazin M., and Cazin J.C. Determination of clozapine in serum by radioreceptor assay versus high-performance liquid chromatography: possible detection of hydroxy-metabolites. J. Clin. Pharm. Ther. 21 (1996) 337-342
21. Ozdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B.K., Albers L.J., Reist C., Roy R., Walkes W., and Afra P. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. J. Clin. Psychopharmacol. 21 (2001) 398-407
22. Perry P.J., Bever K.A., Arndt S., and Combs M.D. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol. Psychiatry 44 (1998) 733-738
23. Rostami-Hodjegan A., Amin A.M., Spencer E.P., Lennard M.S., Tucker G.T., and Flanagan R.J. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J. Clin. Psychopharmacol. 24 (2004) 70-78
24. Schulz E., Fleischhaker C., Clement H.W., and Remschmidt H. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. J. Neural Transm. 104 (1997) 1077-1089
25. Serretti A., De Ronchi D., Lorenzi C., and Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem. 11 (2004) 343-358
26. Spina E., Avenoso A., Facciola G., Scordo M.G., Ancione M., Madia A.G., Ventimiglia A., and Perucca E. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berlin) 148 (2000) 83-89
27. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., Brandish P.E., Pettibone D.J., Scolnick E.M., and Conn P.J. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13674-13679
28. Tuunainen A., Wahlbeck K., and Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr. Res. 56 (2002) 1-10
29. Ulrich S., Baumann B., Wolf R., Lehmann D., Peters B., Bogerts B., and Meyer F.P. Therapeutic drug monitoring of clozapine and relapse-a retrospective study of routine clinical data. Int. J. Clin. Pharmacol. Ther. 41 (2003) 3-13
30. Ulrich S., Wolf R., and Staedt J. Serum level of clozapine and relapse. Ther. Drug Monit. 25 (2003) 252-255
31. Wahlbeck K., Cheine M., Essali A., and Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry 156 (1999) 990-999
32. Wahlbeck K., Cheine M., and Essali M.A. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst. Rev. (2000) (CD000059)
33. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., Mohell N., Harvey S.C., Lameh J., Nash N., Vanover K.E., Olsson R., Jayathilake K., Lee M., Levey A.I., Hacksell U., Burstein E.S., Davis R.E., and Brann M.R. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berlin) 177 (2004) 207-216
34. World Health Organization, 1992. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines.
35. Zhu R., Wang C., Zhao J., Chen Y., and Zhou H. Determination of clozapine and its N-demethylated metabolite in serum by gas chromatography-mass spectrometry with selected ion monitoring. Se. Pu. 16 (1998) 317-320